Trinity Biotech (TRIB) Capital Leases (2016 - 2025)

Trinity Biotech has disclosed Capital Leases across 10 years of filings, most recently posting $10.8 million for Q4 2025.

• Capital Leases for Q4 2025 came in at $10.8 million, up 3.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.8 million (up 3.46% YoY), and the FY2025 annual result was $10.8 million, up 3.46% from the prior year.
• Capital Leases came in at $10.8 million for Q4 2025 at Trinity Biotech, up from $10.5 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $13.9 million in Q4 2021 to a low of $10.5 million in Q4 2024.
• The 5-year median for Capital Leases is $10.9 million (2023), against an average of $11.7 million.
• Across the five-year window, Capital Leases decreased 16.42% in 2021 and climbed 3.46% in 2025, its largest moves.
• Trinity Biotech's Capital Leases stood at $13.9 million in 2021, then decreased by 11.53% to $12.3 million in 2022, then decreased by 11.37% to $10.9 million in 2023, then fell by 3.63% to $10.5 million in 2024, then gained by 3.46% to $10.8 million in 2025.
• The last three Capital Leases figures came in at $10.8 million (Q4 2025), $10.5 million (Q4 2024), and $10.9 million (Q4 2023), per Business Quant data.